About

Global pharmaceutical company Bayer entered the Chinese market in 1882, and it has been a major centre for Bayer’s pharmaceutical production ever since. Now a household name in drug production, research and marketing, Bayer specialises in the development of new molecules for drug production and products serving human, animal and plant health. In Greater China the company employs 10,000 people which is its largest Asian market, and operates the Pharmaceuticals, Consumer Health and Crop Science divisions and several production centres. The in-house legal, compliance and IPR team is led by Greater China general counsel Dr Zhang Xi, and consists of nearly 50 top quality lawyers well versed in the complex regulatory and commercial arrangements of the pharmaceutical industry. In May 2018, Bayer’s legal team advised on the signing of a strategic framework agreement with JD Pharmacy to join its “JD Health Care Plan” and work together to expand each company’s domestic market and customer service. A nominator said, ‘During the past years, Bayer China has grown significantly, conquered many big projects and milestones and made a great contribution to the remarkable success of Bayer Group’s global business and expansion’.